CALGARY, Alberta, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that its late-stage clinical candidate, apabetalone, has been prominently featured in a recent article, titled: “Protein-driven mechanism of multiorgan damage in COVID-19”, in the peer-reviewed journal Medicine in Drug Discovery.
The publication can be viewed using the following LINK.
“Significantly, this is the second peer-reviewed article to highlight apabetalone, the link between BET proteins – the exact target of apabetalone – and COVID-19,” said Donald McCaffrey, President and CEO of Resverlogix. “Of the many therapies discussed in the article, apabetalone is highlighted as a potential treatment for multiorgan damage caused by COVID-19 due to its safety profile and target. The publication suggests the case for apabetalone as a safe, potential COVID-19 therapeutic. We look forward to providing additional data on the effects of apabetalone on COVID-19 infection in our upcoming American Heart Association presentation on November 13, 2020.”
Publication Highlights and Discussions Include:
- The two most frequently mentioned causes of multiorgan damage produced by SARS-CoV-2 (known as COVID-19) are: (i) the direct viral toxicity and (ii) cytokine-release syndrome, or cytokine storm, leading to multiorgan damage
- SARS-CoV-2 (COVID-19) damage has been found to involve several organs / systems, such as neurologic, renal, hepatic, gastrointestinal, hematologic, cardiac, endocrine and dermatological, representing some key areas that apabetalone has already shown clinical benefits towards
- Among the key vulnerable proteins with roles in multiple organs and tissues were BET protein family members (key targets of apabetalone)
- As a direct inhibitor of BET proteins with the potential to beneficially impact inflammation, the authors propose apabetalone as a safe therapeutic with the high likelihood of efficacy against COVID-19
Program Update:
As previously announced, an article published on March 23, 2020 revealed the interaction between SARS-CoV-2 (COVID-19) protein E with BET proteins. Following this finding, Resverlogix put out a call for collaborations, resulting in multiple partnerships, and in parallel initiated preclinical research efforts in-house to further characterize and investigate apabetalone efficacy against COVID-19 infection. From our own studies we have found that beyond the role of BET proteins in viral replication, apabetalone was shown to inhibit expression of Angiotensin-converting enzyme 2 (ACE2), the receptor utilized by the novel coronavirus to enter human cells. Apabetalone is an investigational, phase 3 clinical candidate with safety data in more than 4,000 subjects. Additional details from these multiple programs are expected to be presented in the coming few months.
G1945V